Epileptic spasms: A South African overview of aetiologies, interventions, and outcomes

Sharika V Raga1, Farida Essajee2, Regan Solomons2

  • 1Paediatric Neurology Division, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.

Insights

Infants with epileptic spasms in South Africa often have structural causes and delayed diagnosis, but hormonal therapy like adrenocorticotropic hormone is safe and effective, even with high rates of tuberculosis and HIV.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Infectious Diseases

Background:

  • Epileptic spasms in infants present diagnostic and therapeutic challenges, particularly in resource-limited settings endemic for tuberculosis and HIV.
  • Understanding the causes and treatment outcomes is crucial for improving infant neurological health.

Purpose of the Study:

  • To investigate the aetiologies of epileptic spasms in infants.
  • To evaluate the safety and efficacy of high-dose corticosteroids in managing infantile spasms in a tuberculosis (TB) and human immunodeficiency virus (HIV) endemic region.
  • To analyze treatment delays and developmental outcomes.

Main Methods:

  • Retrospective analysis of infants diagnosed with epileptic spasms at tertiary referral centers in the Western Cape, South Africa.
  • Data collection included age at onset, aetiologies, treatment received, and developmental outcomes.
  • Statistical analysis was performed to compare outcomes between different groups.

Main Results:

  • Structural aetiologies were the most common cause (66%) of epileptic spasms in infants.
  • A shorter lead time to treatment (<1 month) was observed in infants with developmental and epileptic encephalopathy (DEE).
  • Hormonal therapy, including adrenocorticotropic hormone, was safe and effective, achieving spasm resolution in 65% of cases within 14 days, despite high TB and HIV prevalence.

Conclusions:

  • Despite challenges in diagnosis and referral, hormonal therapy is a viable and effective treatment for infantile epileptic spasms in resource-limited, high-burden TB/HIV settings.
  • Delayed recognition of developmental delay and under-referral remain significant issues impacting timely treatment and outcomes.
  • Infants with DEE showed worse developmental outcomes compared to international cohorts, highlighting the need for improved management strategies.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
253
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
545
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
547
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
413
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
810
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
485